Several allosteric modulators (AMs) of the CB 1 receptor have been characterized in vitro, including Org27569, which enhances CB 1 -specific binding of [ 3 H]CP55,940, but behaves as an insurmountable CB 1 -receptor antagonist in several biochemical assays. Although a growing body of research has investigated the molecular actions of this unusual AM, it is unknown whether these actions translate to the whole animal. The purpose of the present study was to determine whether Org27569 would produce effects in well-established mouse behavioral assays sensitive to CB 1 orthosteric agonists and antagonists. Similar to the orthosteric CB 1 antagonist/inverse agonist rimonabant, Org27569 reduced food intake; however, this anorectic effect occurred independently of the CB 1 receptor. Org27569 did not elicit CB 1 -mediated effects alone and lacked efficacy in altering antinociceptive, cataleptic, and hypothermic actions of the orthosteric agonists anandamide, CP55,940, and D 9 -tetrahydrocannabinol. Moreover, it did not alter the discriminative stimulus effects of anandamide in FAAH-deficient mice or D 9 -tetrahydrocannabinol in wild-type mice in the drug discrimination paradigm.
Introduction
The discovery of molecules acting as CB 1 -receptor allosteric modulators (AMs) has fueled interest in developing novel therapeutic agents that elicit minimal cannabimimetic side effects associated with orthosteric CB 1 agonists and antagonists (Price et al., 2005; Horswill et al., 2007; Navarro et al., 2009; Bauer et al., 2012; Pamplona et al., 2012) . Org27569, the most widely investigated CB 1 AM, possesses an unusual pharmacological profile. It increases the binding affinity of CP55,940, a potent and efficacious orthosteric CB 1 agonist, but abates receptor responses in functional assays, including CP55,940-stimulated GTPgS binding, contractions of mouse vas deferens, agonist-induced inhibition of cAMP production, and b-arrestin recruitment assays (Price et al., 2005; Ahn et al., 2012; Baillie et al., 2013) . Other recent work has revealed that b-arrestin plays a role in CB 1biased signaling produced by Org27569 (Ahn et al., 2013) . These paradoxical effects of Org27569 (i.e. enhanced orthosteric agonist binding, but antagonism of signaling events) have been proposed as being mediated by increased rates of CB 1 desensitization that concomitantly cause cAMP levels and hyperpolarization states to return to baseline more rapidly than in the absence of the modulator (Cawston et al., 2013) .
Although Org27569 represents the most extensively studied CB 1 AM reported in the scientific literature, this work is based solely on in-vitro studies. If CB 1 AMs are to be pursued as potential therapeutic agents, it will be important to ensure that prototypical compounds under investigation are active in the whole animal (Ross, 2007) . Thus, the primary objective of the present study was to determine whether Org27569 functions as a CB 1 AM in mice. On the basis of its dampening effect on CB 1 -receptor signaling, we initially assessed whether it would reduce food consumption, a hallmark of CB 1 blockade (Di Marzo and Matias, 2005) . Previously, PSNCBAM-1, which is structurally and pharmacologically similar to Org27569, was shown to reduce food consumption in rats, although CB 1 involvement was not assessed (Horswill et al., 2007) . Thus, in the present study CB 1 (+ / +) and (-/ -) mice were used to infer whether any observed anorectic effects were CB 1 dependent.
In addition, we tested Org27569 in well-established animal models sensitive to the cannabimimetic effects of CB 1 orthosteric agonists, alone and in combination with CP55,940 or anandamide (AEA), which have been used in its in-vitro characterization, as well as with D 9 -tetrahydrocannabinol (THC).
Methods

Subjects
Male and female CB 1 (+ / +) and (-/ -) mice were used in feeding studies, and male C57BL/6J mice (Jackson Laboratory, Bar Harbor, Maine, USA) or FAAH (-/ -) mice were used in drug discrimination experiments. Male ICR mice (Harlan, Indianapolis, Indiana, USA) and C57BL/6 J mice were used in other experiments. All animal protocols were approved by the VCU IACUC and were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals (Resources IoLA, 2011).
Effects of Org27569 on feeding
Following a 1-week acclimation period, CB 1 (+ / +) and (-/-) mice were food-deprived, given an intraperitoneal injection of Org27569 (30 mg/kg), rimonabant (10 mg/kg; positive control), or vehicle at 23 h, and placed in a plastic cage with access to water. A premeasured amount (2.3-2.6 g) of sweet cereal (Froot Loops; Kellogg NA Co., Battle Creek, Michigan, USA) or standard chow (Teklad, Madison, Wisconsin, USA) was placed in the test cage from 24 to 26h. All mice received each treatment condition in a counterbalanced design, with at least 96 h between test days.
Cannabimimetic pharmacological effects of Org27569 in combination with orthosteric agonists
Mice were tested for (i) catalepsy in the bar test (60 s); (ii) antinociception in the warm-water (521C) tail withdrawal test (10 s cutoff); and (iii) hypothermia by measuring rectal temperature (Falenski et al., 2010) . Antinociception was calculated as the percentage of maximum possible effect (MPE):
:
Cumulative dose-response relationships were assessed for AEA, CP55,940, and THC. Org27569 quantification in blood and brain
Org27569 was administered either intraperitoneally (30 mg/kg) or intracerebroventricularly (100 mg) and levels of the drug were quantified, respectively, in the blood and brain, or brain, according to established methods (Kinsey et al., 2009 ), using the HPLC/MS/MS method with an Applied Bio systems (Carlsbad, CA, USA) 3200 Q trap with a turbo V source for TurboIonSpray attached to a Shimadzu SCL HPLC system (Kyoto, Japan). Chromatographic separation was performed using a Discovery HS C 18 , 2.1 Â 150 mm, 3 mm column (Supelco, St. Louis, MO, USA).
Drugs
Org27569 (University of Aberdeen, Scotland) and CP55,940, THC, AEA, PF-3845 (FAAH inhibitor that prevents AEA degradation), and rimonabant (CB 1 antagonist/inverse agonist; NIDA, Bethesda, Maryland, USA) were dissolved in ethanol (Pharmco Products Inc., Brookfield, Connecticut, USA), Emulphor-620 (Rhodia, Cranbury, New Jersey, USA), and saline, in a ratio of 1 : 1 : 18. Org27569 was administered systemically in a volume of 20 ml/g, and for intracerebroventricular injection it was dissolved in 100% dimethyl sulfoxide and administered in a volume of 5 ml. The injection volume for all other systemically administered compounds was 10 ml/g.
Data analysis
All data are reported as mean±SEM and were analyzed using analysis of variance. Dunnett's test was used for the dose-response experiments and the Bonferroni-Dunn test was used for other post-hoc comparisons. Analyses were considered significant at P values less than 0.05.
Results
Org27569 (30 mg/kg) significantly reduced consumption of standard chow (data not shown) and sweet cereal in both CB 1 (-/ -) and (+ / +) mice [genotype by drug treatment interaction: F(2,60) = 11.1, P < 0.001; Fig. 1a ]. In contrast, rimonabant (positive control) reduced intake in CB 1 (+ / +) mice only. Org27569 did not alter the discriminative stimulus effects of or substitute for AEA ( Fig. 1b and c) or THC (5.6 mg/kg intraperitoneally; data not shown) in FAAH (-/ -) mice and C57BL/6J mice, respectively. Moreover, Org27569 alone did not produce antinociception, catalepsy, or hypothermia. Further, Org27569 did not reduce the cataleptic, antinociceptive, or hypothermic effects produced by AEA in PF-3845-treated mice or FAAH (-/ -) mice (data not shown). In fact, in FAAH (-/ -) mice, Org27569 produced small but significant increases in the potency of AEA (potency ratio with 95% confidence interval) to elicit catalepsy [1.3 (1.1-1.7)] and antinociception [1.9 (1.3-2.8)], but not hypothermia [1.1 (0.9-1.4)], compared with vehicle-pretreated FAAH (-/ -) mice (data not shown). Org27569 (30 mg/kg intraperitoneally) was detected in the brain (4.09±0.39 mg/mg) and blood (3.71±1.77 mg/ml) 1 h after intraperitoneal administration. In an effort to assess the impact of further increasing brain levels of this compound, Org27569 (100 mg) was administered intracerebroventricularly. Despite achieving increased brain levels of Org27569 (i.e. 13.4±2.5 and 10.56±1.8 mg/mg at 0.75 and 1.75 h after injection, respectively), this compound did not alter the antinociceptive, cataleptic, or hypothermic dose-response relationships of intraperitoneally administered CP55,940 (0.1, 0.3, and 1 mg/kg; Fig. 2 ). Finally, Org27569 (30 mg/kg, intraperitoneal) did not affect these pharmacological endpoints produced by intraperitoneally administered THC (3, 10, 30, and 100 mg/kg; data not shown).
Discussion
This study represents the first systematic evaluation of the CB 1 AM Org27569 in well-established in-vivo assays sensitive to CB 1 orthosteric agonists and antagonists. Org27569 produced hypophagic effects in both CB 1 (-/ -) and (+ / +) mice. This finding is in contrast to that for rimonabant, which reduced food consumption only in CB 1 (+ / +) mice. These results indicate that the CB 1 receptor is dispensable for Org27569-induced hypophagia. Org27569 did not elicit relevant behavioral or cannabimimetic effects when administered alone or in combination with three distinct CB 1 orthosteric agonists. Specifically, it did not substitute for either AEA or THC and did not modify the discriminative stimulus effects of either agonist in the drug discrimination paradigm. Moreover, Org27569 did not alter the cataleptic, antinociceptive, or hypothermic effects of THC in wild-type mice or AEA in PF-3845treated FAAH (+ / +) mice, although it slightly enhanced AEA-induced antinociception and catalepsy in FAAH (-/ -) mice. Although pharmacokinetic issues represent a potential hurdle when studying drugs in the whole animal, it is noteworthy that 1 h after intraperitoneal administration, Org27569 was detected at equivalent concentrations in the brain and blood. Moreover, direct administration of Org27569 to the brain yielded a 2-3-fold increase in its levels in the brain; however, it still did not alter the cataleptic, antinociceptive, or hypothermic effects of systemically administered CP55,940.
The findings that Org27569 did not elicit CB 1 -mediated effects alone and lacked efficacy in altering the actions of orthosteric agonists in established murine behavioral assays sensitive to cannabimimetic activity indicate a lack of translation between its interesting in-vitro actions at the CB 1 receptor and its effects in the whole animal. These results question the utility of Org27569 as a tool to elucidate CB 1 allosteric site(s), if these compounds are to be pursued as potential pharmacotherapies. The development of new CB 1 AMs with a pharmacology that extends from the molecular level to the whole animal is needed.
